Cosmo's Clascoterone Posts Strong 12-Month Hair Loss Data
Clascoterone 5% solution delivered 2.39-fold greater hair count improvement at 12 months. Cosmo will file for FDA approval in early 2027, the first new mechanism in 30 years.
Updated
The takeaway
- SCALP 1 and SCALP 2 enrolled 1,465 men at 51 centers across the U.S. and Europe.
- Full-year clascuterone users showed a 2.39-fold greater improvement in hair counts than those who stopped at six months, plus 24.5% higher treatment satisfaction.
- Cosmo Pharmaceuticals plans to file for FDA approval in early 2027; clascoterone would be the first topical androgen receptor inhibitor for androgenetic alopecia.
Cosmo Pharmaceuticals has reported 12-month data from two phase 3 trials of clascoterone 5% topical solution, and the numbers point to a potential landmark in androgenetic alopecia treatment: men who used the drug for a full year showed a 2.39-fold greater improvement in hair counts than those who stopped after six months.
The company plans to file for FDA approval in early 2027, according to Dermatology Times. If cleared, clascoterone would become the first topical androgen receptor inhibitor for androgenetic alopecia — and the first new mechanism of action for male pattern hair loss in more than 30 years.
The Trial Setup
The SCALP 1 and SCALP 2 studies enrolled 1,465 men with mild to moderate androgenetic alopecia — the medical term for male pattern hair loss — at 51 centers across the U.S. and Europe.
The trials ran in two stages. For the first six months, researchers randomly assigned participants to either clascoterone or a vehicle, an inactive version of the solution. Responders to clascoterone were then re-randomized to keep using the drug or switch to the vehicle for another six months.
Continuing treatment paid off. Full-year users saw hair counts in the treated area keep rising. They also reported a 24.5 percent relative improvement in treatment satisfaction compared with those who switched to the vehicle.
How It Works
Clascoterone is an androgen receptor inhibitor. It reduces signaling from dihydrotestosterone, or DHT, the hormone driving male pattern hair loss. Very little of the compound absorbs into the body, and the trial data support its use as a long-term, continuous treatment.
Safety data back that claim. Across all 12 months, safety and tolerability were comparable to the vehicle, with no significant systemic hormonal side effects.
"AGA requires long-term management, so safety matters enormously. These data are encouraging because they show a profile that supports chronic use over time," said Maria Hordinsky, MD, professor of dermatology at the University of Minnesota and clinical investigator in the phase 3 program.
Why Dermatologists Are Watching
Michael H. Gold, MD, founder of Gold Skin Care Center, framed the stakes beyond the scalp.
"Male pattern hair loss is far more than a cosmetic concern. It affects confidence, identity, emotional wellbeing, and quality of life for millions of men every day. Yet physicians have had very few truly new tools to offer patients for decades," Gold said. "Seeing a potential new FDA-approved topical treatment with a differentiated mechanism, a favorable safety profile, and efficacy that continues through 12 months is highly meaningful."
What Comes Next
Clascuterone is not approved yet. Cosmo must complete its regulatory filings first, with the FDA submission planned for early 2027. Until then, men considering treatment can consult a dermatologist about currently available options.
For a category that has gone more than three decades without a new mechanism of action, an FDA filing in early 2027 would mark the industry's most significant regulatory milestone in male pattern hair loss in a generation.
Original: dermatologytimes.com
More from Grace Kim
Show full bio
Correspondent covering media and advertising at Eurasian Beauty Journal.
34 articles
